Advanced breast cancer: A phase II trial with gemcitabine

Journal of Clinical Oncology

Volumn 13, Issue 11, 1995, Pages 2731-2736

  Carmichael, James ^a   Possinger, Kurt ^b   Phillip, Philip ^b   Beykirch, Maria ^b   Kerr, Helen ^b   Walling, Jackie ^b   Harris, Adrian L ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0028799915     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.11.2731     Document Type: Article

References (26)

1. Huang P, Chubb S, Hertel LW, et al: Mechanism of action of 2′,2′-difluorodeoxycytidine triphosphate on DNA synthesis. Proc Am Assoc Cancer Res 31:426, 1990 (abstr)
2. Huang P, Chubb S, Hertel L, et al: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117, 1991
3. Plunkett W, Gandhi V, Chubb S, et al: 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides 8:775-785, 1989
4. Heinemann V, Hertel L, Grindey GB, et al: Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate (dFdCTP). Proc Am Assoc Cancer Res 29:504, 1988 (abstr)
5. Xu Y-Z, Plunkett W: Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 44:1819-1827, 1992
6. Hertel LW, Boder GB, Kroin JS, et al: Evaluation of the antitumor activity of gemcitabine, (difluoro-2′-deoxycytidine). Cancer Res 50:4417-22, 1990
7. O'Rourke TJ, Brown TD, Havlin K, et al: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 30:417-418, 1994
8. Poplin E, Corbett T, Flaherty, et al: Difluorodeoxycytidine (dFdC)-gemcitabine. A phase I study. Invest New Drugs 10:165-170, 1992
9. Kaye SB. Editorial. Gemcitabine: Current status of phase I and II trials. J Clin Oncol 12:1527-1531, 1994
10. Abbruzzese JL, Grunewald R, Weeks EA, et al: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
11. Abratt RP, Bezwoda WR, Falkson G, et al: Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study. J Clin Oncol 12:1535-1540, 1994
12. Shepherd FA, Gatzemeier U, Gottfried M, et al: An extended phase II study of gemcitabine in non-small cell lung cancer. Proc Am Assoc Cancer Res 12:24, 1993 (abstr 1096)
13. Anderson H, Lund B, Bach F, et al: Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: A phase II study. J Clin Oncol 12:1821-1826, 1994
14. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst 86:1530-1533, 1994
15. Cormier Y, Eisenhauer E, Muldal A, et al: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 5:283-285, 1994
16. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
17. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979, p 48
18. O Brien MER, Talbot DC, Smith IE: Carboplatin in the treatment of advanced breast cancer: A phase II study using a pharmacokinetically guided dose schedule. J Clin Oncol 11:2112-2117, 1993
19. Andersson M, Daugaard S, Von der Maase H, et al: Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomized study. Cancer Treat Rep 70:1181-1186, 1986
20. Schornagel JH, Van der Vegt S, Verweij J, et al: Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol 3:549-552, 1992
21. Bezwoda WR, Seymour L, Ariad S: High-dose etoposide in treatment of metastatic breast cancer. Oncol 49:104-107, 1992
22. Mross K, Bohn C, Edler L, et al: Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer. Ann Oncol 4:45-50, 1993
23. Jones WG: Effective palliation of advanced breast cancer with weekly low dose epirubicin. Eur J Cancer Clin Oncol 25:357-360, 1989
24. Fumoleau P, Delgado FM, Delozier T, et al: Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993
25. Klaassen U, Diergarten K, Dittrich CH, et al: Randomized trial of two doses of Taxol in metastatic breast cancer: An interim analysis. Onkologie 17:86-90, 1994
26. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991